Symbols / TNGX $18.68 +4.47%
TNGX Chart
About
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.67B |
| Enterprise Value | 2.36B | Income | -101.59M | Sales | 62.38M |
| Book/sh | 2.55 | Cash/sh | 2.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 137 | IPO | — |
| P/E | — | Forward P/E | -12.19 | PEG | — |
| P/S | 42.73 | P/B | 7.33 | P/C | — |
| EV/EBITDA | -21.61 | EV/Sales | 37.76 | Quick Ratio | 15.83 |
| Current Ratio | 16.32 | Debt/Eq | 9.70 | LT Debt/Eq | — |
| EPS (ttm) | -0.87 | EPS next Y | -1.53 | EPS Growth | — |
| Revenue Growth | -100.00% | Earnings | 2026-05-11 | ROA | -19.45% |
| ROE | -37.23% | ROIC | — | Gross Margin | -111.86% |
| Oper. Margin | -178.39% | Profit Margin | -162.85% | Shs Outstand | 142.69M |
| Shs Float | 67.82M | Short Float | 39.25% | Short Ratio | 17.80 |
| Short Interest | — | 52W High | 18.97 | 52W Low | 1.03 |
| Beta | 1.81 | Avg Volume | 3.41M | Volume | 3.44M |
| Target Price | $19.67 | Recom | Strong_buy | Prev Close | $17.88 |
| Price | $18.68 | Change | 4.47% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.67
Mean price target
2. Current target
$18.68
Latest analyst target
3. DCF / Fair value
$-7.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.68
Low
$14.00
High
$27.00
Mean
$19.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Mizuho | Outperform → Outperform | $20 |
| 2026-03-09 | main | Stifel | Buy → Buy | $24 |
| 2026-03-06 | main | Wedbush | Outperform → Outperform | $19 |
| 2026-03-06 | main | Guggenheim | Buy → Buy | $20 |
| 2026-03-06 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2026-02-23 | init | Mizuho | — → Outperform | $19 |
| 2026-02-06 | main | Guggenheim | Buy → Buy | $18 |
| 2026-01-16 | main | Piper Sandler | Overweight → Overweight | $14 |
| 2025-12-04 | init | Stifel | — → Buy | $15 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-11-18 | main | B. Riley Securities | Buy → Buy | $14 |
| 2025-10-24 | main | Guggenheim | Buy → Buy | $12 |
| 2025-08-19 | init | Piper Sandler | — → Overweight | $11 |
| 2025-08-06 | main | Guggenheim | Buy → Buy | $10 |
| 2025-04-14 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-12-05 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-11-11 | main | B. Riley Securities | Buy → Buy | $8 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-11-07 | main | Guggenheim | Buy → Buy | $8 |
| 2024-10-28 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
- TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - Yahoo Finance Fri, 06 Mar 2026 08
- Tango Therapeutics, Inc. $TNGX Shares Sold by Trv Gp Iv LLC - MarketBeat Sat, 14 Mar 2026 11
- Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn? - simplywall.st Mon, 16 Mar 2026 18
- Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - The Motley Fool Wed, 04 Mar 2026 08
- Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com Fri, 06 Mar 2026 14
- $TNGX stock is up 25% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Mar 2026 19
- Pancreatic cancer bet: Tango sets 2026 pivotal trial with $343M war chest - Stock Titan hu, 05 Mar 2026 08
- Farallon Capital Management LLC Buys 1,600,000 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat Mon, 16 Mar 2026 10
- Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing - Yahoo Finance Wed, 04 Mar 2026 08
- $TNGX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 08
- Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following Earnings - Yahoo Finance Fri, 13 Mar 2026 18
- Mizuho Forecasts Strong Price Appreciation for Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat Wed, 11 Mar 2026 13
- Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st Sat, 14 Mar 2026 18
- $TNGX stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Wed, 14 Jan 2026 08
- Tango Therapeutics (NASDAQ:TNGX) Hits New 12-Month High - Should You Buy? - MarketBeat Mon, 16 Mar 2026 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 20251 | 303765 | — | Sale at price 15.00 per share. | CRYSTAL ADAM S | Officer | — | 2026-03-05 00:00:00 | D |
| 1 | 54345 | 694208 | — | Sale at price 12.77 per share. | CRYSTAL ADAM S | Officer | — | 2026-02-25 00:00:00 | D |
| 2 | 10317 | 126531 | — | Sale at price 12.26 - 12.90 per share. | BECKMAN DANIELLA | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 3 | 30519 | 374294 | — | Sale at price 12.26 - 12.90 per share. | WEBER BARBARA L | Officer and Director | — | 2026-02-03 00:00:00 | D |
| 4 | 18452 | 226300 | — | Sale at price 12.26 - 12.90 per share. | CRYSTAL ADAM S | Officer | — | 2026-02-03 00:00:00 | D |
| 5 | 44330 | — | — | Stock Award(Grant) at price 0.00 per share. | BECKMAN DANIELLA | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 6 | 37522 | — | — | Stock Award(Grant) at price 0.00 per share. | WEBER BARBARA L | Officer and Director | — | 2026-02-02 00:00:00 | D |
| 7 | 47460 | — | — | Stock Award(Grant) at price 0.00 per share. | CRYSTAL ADAM S | Officer | — | 2026-02-02 00:00:00 | D |
| 8 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | PETERS MALTE | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 9 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEE SUNG | Director | — | 2026-01-02 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -109.01M | -143.10M | -111.76M | -109.46M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -101.59M | -130.30M | -101.74M | -108.18M |
| ReconciledDepreciation | 2.28M | 2.50M | 2.42M | 1.61M |
| EBITDA | -109.01M | -143.10M | -111.76M | -109.46M |
| EBIT | -111.29M | -145.59M | -114.17M | -111.07M |
| NetInterestIncome | 5.63M | 7.89M | 6.62M | 1.46M |
| InterestIncome | 5.63M | 7.89M | 6.62M | 1.46M |
| NormalizedIncome | -101.59M | -130.30M | -101.74M | -108.18M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -101.59M | -130.30M | -101.74M | -108.18M |
| TotalExpenses | 173.67M | 187.66M | 150.70M | 135.93M |
| TotalOperatingIncomeAsReported | -111.29M | -145.59M | -114.17M | -111.07M |
| DilutedAverageShares | 109.23M | 94.57M | 87.82M | 62.11M |
| BasicAverageShares | 109.23M | 94.57M | 87.82M | 62.11M |
| DilutedEPS | -1.19 | -1.08 | -1.23 | -0.94 |
| BasicEPS | -1.19 | -1.08 | -1.23 | -0.94 |
| DilutedNIAvailtoComStockholders | -101.59M | -130.30M | -101.74M | -108.18M |
| NetIncomeCommonStockholders | -101.59M | -130.30M | -101.74M | -108.18M |
| NetIncome | -101.59M | -130.30M | -101.74M | -108.18M |
| NetIncomeIncludingNoncontrollingInterests | -101.59M | -130.30M | -101.74M | -108.18M |
| NetIncomeContinuousOperations | -101.59M | -130.30M | -101.74M | -108.18M |
| TaxProvision | 4.00K | 208.00K | 134.00K | 54.00K |
| PretaxIncome | -101.59M | -130.09M | -101.61M | -108.12M |
| OtherIncomeExpense | 4.07M | 7.61M | 5.94M | 1.49M |
| OtherNonOperatingIncomeExpenses | 4.07M | 7.61M | 5.94M | 1.49M |
| NetNonOperatingInterestIncomeExpense | 5.63M | 7.89M | 6.62M | 1.46M |
| InterestIncomeNonOperating | 5.63M | 7.89M | 6.62M | 1.46M |
| OperatingIncome | -111.29M | -145.59M | -114.17M | -111.07M |
| OperatingExpense | 173.67M | 187.66M | 150.70M | 135.93M |
| ResearchAndDevelopment | 132.16M | 143.92M | 115.20M | 105.91M |
| SellingGeneralAndAdministration | 41.51M | 43.75M | 35.50M | 30.02M |
| GeneralAndAdministrativeExpense | 41.51M | 43.75M | 35.50M | 30.02M |
| OtherGandA | 41.51M | 43.75M | 35.50M | 30.02M |
| TotalRevenue | 62.38M | 42.07M | 36.53M | 24.86M |
| OperatingRevenue | 62.38M | 42.07M | 36.53M | 24.86M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 135.94M | 107.73M | 102.20M | 88.18M |
| ShareIssued | 135.94M | 107.73M | 102.20M | 88.18M |
| TotalDebt | 33.57M | 36.49M | 38.92M | 41.13M |
| TangibleBookValue | 346.18M | 199.52M | 253.11M | 249.48M |
| InvestedCapital | 346.18M | 199.52M | 253.11M | 249.48M |
| WorkingCapital | 332.08M | 228.17M | 300.60M | 319.73M |
| NetTangibleAssets | 346.18M | 199.52M | 253.11M | 249.48M |
| CapitalLeaseObligations | 33.57M | 36.49M | 38.92M | 41.13M |
| CommonStockEquity | 346.18M | 199.52M | 253.11M | 249.48M |
| TotalCapitalization | 346.18M | 199.52M | 253.11M | 249.48M |
| TotalEquityGrossMinorityInterest | 346.18M | 199.52M | 253.11M | 249.48M |
| StockholdersEquity | 346.18M | 199.52M | 253.11M | 249.48M |
| GainsLossesNotAffectingRetainedEarnings | 224.00K | 336.00K | 186.00K | -3.71M |
| OtherEquityAdjustments | 224.00K | 336.00K | 186.00K | -3.71M |
| RetainedEarnings | -603.15M | -501.56M | -371.26M | -269.51M |
| AdditionalPaidInCapital | 948.97M | 700.63M | 624.08M | 522.61M |
| CapitalStock | 136.00K | 108.00K | 102.00K | 88.00K |
| CommonStock | 136.00K | 108.00K | 102.00K | 88.00K |
| TotalLiabilitiesNetMinorityInterest | 52.51M | 116.97M | 149.46M | 186.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 30.83M | 78.81M | 103.52M | 131.45M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 0.00 | 44.77M | 66.68M | 92.09M |
| NonCurrentDeferredRevenue | 0.00 | 44.77M | 66.68M | 92.09M |
| LongTermDebtAndCapitalLeaseObligation | 30.83M | 34.04M | 36.84M | 39.36M |
| LongTermCapitalLeaseObligation | 30.83M | 34.04M | 36.84M | 39.36M |
| CurrentLiabilities | 21.68M | 38.17M | 45.94M | 55.55M |
| OtherCurrentLiabilities | 1.29M | 1.74M | 1.29M | 1.27M |
| CurrentDeferredLiabilities | 0.00 | 17.62M | 25.67M | 31.79M |
| CurrentDeferredRevenue | 0.00 | 17.62M | 25.67M | 31.79M |
| CurrentDebtAndCapitalLeaseObligation | 2.74M | 2.45M | 2.08M | 1.77M |
| CurrentCapitalLeaseObligation | 2.74M | 2.45M | 2.08M | 1.77M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.69M | |||
| PayablesAndAccruedExpenses | 17.65M | 16.36M | 16.90M | 20.72M |
| CurrentAccruedExpenses | 16.47M | 14.76M | 14.11M | 16.23M |
| Payables | 1.18M | 1.60M | 2.79M | 4.49M |
| TotalTaxPayable | 0.00 | 35.00K | 52.00K | |
| IncomeTaxPayable | 0.00 | 35.00K | 52.00K | |
| AccountsPayable | 1.18M | 1.60M | 2.79M | 4.45M |
| TotalAssets | 398.69M | 316.49M | 402.57M | 436.47M |
| TotalNonCurrentAssets | 44.93M | 50.15M | 56.03M | 61.20M |
| OtherNonCurrentAssets | 2.44M | 2.57M | 2.61M | 3.43M |
| NetPPE | 42.49M | 47.58M | 53.42M | 57.77M |
| AccumulatedDepreciation | -10.54M | -8.36M | -5.99M | -3.68M |
| GrossPPE | 53.03M | 55.94M | 59.41M | 61.45M |
| Leases | 3.72M | 2.87M | 2.86M | 2.78M |
| ConstructionInProgress | 0.00 | 152.00K | 38.00K | 8.00K |
| OtherProperties | 44.56M | 48.41M | 52.30M | 54.61M |
| MachineryFurnitureEquipment | 4.75M | 4.51M | 4.21M | 4.06M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 353.76M | 266.34M | 346.54M | 375.27M |
| OtherCurrentAssets | 10.19M | 8.43M | 8.80M | 6.57M |
| RestrictedCash | 428.00K | 0.00 | 856.00K | 567.00K |
| PrepaidAssets | 4.52M | |||
| Receivables | 0.00 | 2.00M | 2.00M | |
| AccountsReceivable | 0.00 | 2.00M | 2.00M | |
| CashCashEquivalentsAndShortTermInvestments | 343.14M | 257.92M | 336.88M | 366.13M |
| OtherShortTermInvestments | 230.86M | 188.39M | 270.50M | 306.17M |
| CashAndCashEquivalents | 112.28M | 69.53M | 66.39M | 59.97M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -139.93M | -132.25M | -119.51M | -116.77M |
| IssuanceOfDebt | 0.00 | 342.11M | ||
| IssuanceOfCapitalStock | 212.40M | 41.72M | 80.02M | 0.00 |
| CapitalExpenditure | -1.05M | -754.00K | -1.53M | -7.69M |
| EndCashPosition | 114.85M | 72.10M | 69.81M | 63.96M |
| BeginningCashPosition | 72.10M | 69.81M | 63.96M | 145.02M |
| ChangesInCash | 42.75M | 2.29M | 5.85M | -81.07M |
| FinancingCashFlow | 222.50M | 47.66M | 82.41M | 1.61M |
| CashFlowFromContinuingFinancingActivities | 222.50M | 47.66M | 82.41M | 1.61M |
| NetOtherFinancingCharges | -36.00K | 448.00K | -8.00K | -15.84M |
| ProceedsFromStockOptionExercised | 10.14M | 5.94M | 1.94M | 1.62M |
| NetPreferredStockIssuance | 0.00 | 29.99M | ||
| PreferredStockIssuance | 0.00 | 29.99M | ||
| NetCommonStockIssuance | 212.40M | 41.72M | 80.02M | 0.00 |
| CommonStockIssuance | 212.40M | 41.72M | 80.02M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 342.11M | ||
| NetLongTermDebtIssuance | 0.00 | 342.11M | ||
| LongTermDebtIssuance | 0.00 | 342.11M | ||
| InvestingCashFlow | -40.87M | 86.13M | 41.43M | 26.40M |
| CashFlowFromContinuingInvestingActivities | -40.87M | 86.13M | 41.43M | 26.40M |
| NetInvestmentPurchaseAndSale | -39.82M | 86.88M | 42.95M | 34.09M |
| SaleOfInvestment | 224.64M | 327.77M | 353.53M | 242.59M |
| PurchaseOfInvestment | -264.46M | -240.89M | -310.57M | -208.50M |
| NetPPEPurchaseAndSale | -1.05M | -754.00K | -1.53M | -7.69M |
| PurchaseOfPPE | -1.05M | -754.00K | -1.53M | -7.69M |
| OperatingCashFlow | -138.89M | -131.50M | -117.98M | -109.08M |
| CashFlowFromContinuingOperatingActivities | -138.89M | -131.50M | -117.98M | -109.08M |
| ChangeInWorkingCapital | -67.20M | -31.75M | -37.97M | -18.49M |
| ChangeInOtherWorkingCapital | -62.38M | -29.97M | -31.53M | -16.86M |
| ChangeInOtherCurrentLiabilities | -3.03M | -2.14M | -2.44M | 1.70M |
| ChangeInOtherCurrentAssets | -299.00K | 43.00K | -41.00K | -10.00M |
| ChangeInPayablesAndAccruedExpense | 279.00K | -50.00K | -3.73M | 8.73M |
| ChangeInAccruedExpense | 1.10M | 1.13M | -2.03M | 7.63M |
| ChangeInPayable | -825.00K | -1.18M | -1.71M | 1.10M |
| ChangeInAccountPayable | -825.00K | -1.18M | -1.71M | 1.10M |
| ChangeInPrepaidAssets | -1.76M | 370.00K | -2.23M | -2.06M |
| ChangeInReceivables | 0.00 | 0.00 | 2.00M | 0.00 |
| ChangesInAccountReceivables | 0.00 | 0.00 | 2.00M | 0.00 |
| OtherNonCashItems | 3.88M | 3.77M | 3.63M | 1.75M |
| StockBasedCompensation | 26.43M | 28.90M | 19.08M | 14.23M |
| AmortizationOfSecurities | -2.69M | -4.62M | -3.39M | 0.00 |
| DepreciationAmortizationDepletion | 2.28M | 2.50M | 2.42M | 1.61M |
| DepreciationAndAmortization | 2.28M | 2.50M | 2.42M | 1.61M |
| Depreciation | 2.28M | 2.50M | 2.42M | 1.61M |
| NetIncomeFromContinuingOperations | -101.59M | -130.30M | -101.74M | -108.18M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TNGX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|